DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients

NCT06782022 | Completed Phase 2

• 1 other identifier: NL70778.075.19
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale: Fluorouracil (5-FU) are broadly used in chemotherapeutic regimens for the treatment of cancers. Dihydropyrimidine dehydrogenase (DPD) is a major enzyme in the 5-FU metabolism pathway. Patients with a partial or complete DPD deficiency have a strongly reduced capacity to metabolize 5-FU which may result in severe or life-threatening toxicity when treated with a standard dose of fluoropyrimidines. A partial DPD deficiency is present in 3-5% of the North American and European population. DPD deficiency is most often caused by genetic variants in the gene encoding DPD (DPYD). The four DPYD variants considered most clinically relevant and with statistically significant association with severe toxicity are DPYD\*2A (rs3918290, c.1905+1G\>A, IVS14+1G\>A), c.2846A\>T (rs67376798, D949V), c.1679T\>G (rs55886062, DPYD\*13, I560S), and c.1236G\>A (rs56038477, E412E, in haplotype B3). Prospective testing for DPD deficiency can prevent severe toxicity or mortality. Several methods have been proposed for detection of DPD deficiency, based on either genotyping of DPYD or measurement of the DPD phenotype. However, DPD deficiency is not the only factor associated with variable concentrations of 5-FU. 5-FU displays an exposure-response relationship between systemic exposure and clinical events. Therapeutic Drug Monitoring (TDM) or pharmacokinetics (PK)-guided dosing of 5-FU is also considered as an alternative to ensure an acceptable exposure of 5-FU. Upfront DPD screening combined with PK guided 5-FU dosing as a tool to personalize treatment has never been studied before. In this study, we aim to investigate the PK of 5-FU for the 4 most common DPYD genetic variants, in order to better define a safe starting dose for 5-FU in DPD deficient patients. Objectives: The primary objective of this study is to investigate the clearance of 5-FU for the 4 most common DPYD gene variants compared to the clearance of 5-FU in DPYD wild-type patients. The secondary objectives of this study are to determine the toxicity incidence and the extent of DPD deficiency as measured by Uracil Loading Test (ULT) for the 4 most common DPYD variants, to evaluate the safety and tolerability of reduced starting dose of 5-FU in patients with DPD deficiency, to demonstrate the ability to achieve a target AUC range, to establish that PK-guided 5-FU dosing decreases the incidence of 5-FU related toxicities, to establish the sensitivity, specificity and predictive values of the DPYD genotyping test and to optimize the sampling moment of 5-FU in order to minimize patient discomfort related to TDM procedures Study design: The study is designed as a single-centre prospective inception cohort study. All patients will be screened for DPD deficiency by DPYD genotyping and separated into two groups; DPYD common variants and control group. Patients with DPYD wild-type but who experience CTC grade 3-4 toxicity will also be included in this study as a toxicity group. Patients will be tested with an oral ULT to identify their DPD phenotype and measured an endogenous U/DHU ratio. Therapeutic drug monitoring will be performed to follow-up patients' 5-FU plasma concentration after start chemotherapy treatment. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached or maximum 4 treatment cycles is reached. Study population: All gastrointestinal cancer patients aged 18 years and older who are scheduled to receive treatment with fluoropyrimidine based chemotherapy. Treatment: All patients will be treated with a standard chemotherapy regimen for their respective gastrointestinal cancer. Only 5-FU based regimens will be considered for this study. Patients will receive adjusted 5-FU doses based on their condition, including body surface area, gene activity score or DPD status, and steady state AUC from the previous dose, until their AUC reaches a target range. Patients will continue to receive regular treatment, as long as needed and/or tolerated. Main study parameters: The primary outcome of the study is the clearance of 5-FU at steady state (Clss) measured in ml/min. Among cancer patients treated with 5-FU, we will compare the variation in clearance between the four common DPYD variant allele carriers and DPYD wild-type carriers. The secondary study parameters are the incidence of 5-FU related toxicities, U/DHU ratio, DPD phenotype (EM, IM, and PM), 5-FU doses, dosage adjustment and time to reach target AUC (cycle number).

Conditions

Gastrointestinal Cancers

Keywords

dihydropyrimidine dehydrogenase; 5-fluorouracil; genotyping; phenotyping; therapeutic drug monitoring; fluoropyrimidines

Outcome Measures

Primary Outcomes (1)

• 5-Fluorouracil pharmacokinetics

  The primary objective of this study is to investigate the clearance of 5-FU at steady state (Clss) for the 4 most common DPYD gene variants, compared to the clearance of 5-FU at steady state (Clss) in DPYD wild-type patients and the clearance of 5-FU at steady state (Clss) in assumed DPYD wild-type patients with early grade 3-4 toxicity in order to better define a safe starting dose for 5-FU in DPD deficient patients.

  From enrollment to the end of treatment cycle 4 (the length of each cycle is 14 days)

Secondary Outcomes (6)

• 5-FU dose needed to reach target AUC

  From enrollment to the end of treatment cycle 4 (the length of each cycle is 14 days)

• DPD phenotyping result

  From enrollment to the end of treatment cycle 4 (the length of each cycle is 14 days)

• Safety and tolerability

  From enrollment to the end of treatment cycle 4 (the length of each cycle is 14 days)

• Number of cycles to reach target AUC

  From enrollment to the end of treatment cycle 4 (the length of each cycle is 14 days)

• Sensitivity, specificity and predictive value of DPYD genotyping

  From enrollment to the end of treatment cycle 4 (the length of each cycle is 14 days)

Study Arms (5)

Group E, DPYD wild type controls

OTHER

Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.

Drug: 5-Fluoro-Uracil

Group A, DPYD E412E (c.1236G>A; rs56038477) heterozygotes

EXPERIMENTAL

Patients will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected once at least 4 hour after the start of the perfusion in the morning between 8 and 10 a.m. 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached or a maximum 4 treatment cycles has been reached. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.

Drug: 5-Fluoro-Uracil

Group B, DPYD IVS14 ds+1G>A (*2A; c.1905+1G>A; rs3918290) heterozygotes

EXPERIMENTAL

Patients will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected once at least 4 hour after the start of the perfusion in the morning between 8 and 10 a.m. 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached or a maximum 4 treatment cycles has been reached. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.

Drug: 5-Fluoro-Uracil

Group C, DPYD D949V (c.2846A>T; rs67376798) heterozygotes

EXPERIMENTAL

Patients will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected once at least 4 hour after the start of the perfusion in the morning between 8 and 10 a.m. 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached or a maximum 4 treatment cycles has been reached. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.

Drug: 5-Fluoro-Uracil

Group D, DPYD I560S (*13; c.1679T>G; rs55886062) heterozygotes

EXPERIMENTAL

Patients will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected once at least 4 hour after the start of the perfusion in the morning between 8 and 10 a.m. 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached or a maximum 4 treatment cycles has been reached. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.

Drug: 5-Fluoro-Uracil

Interventions

5-Fluoro-Uracil DRUG

Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion. Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached.

Group A, DPYD E412E (c.1236G>A; rs56038477) heterozygotes; Group B, DPYD IVS14 ds+1G>A (*2A; c.1905+1G>A; rs3918290) heterozygotes; Group C, DPYD D949V (c.2846A>T; rs67376798) heterozygotes; Group D, DPYD I560S (*13; c.1679T>G; rs55886062) heterozygotes; Group E, DPYD wild type controls

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age 18 years and older
• histological proof of gastro-intestinal cancer
• patient is considered for treatment with capecitabine or 5-FU
• acceptable safety laboratory values
• ECOG performance status 0-2
• able and willing to give written informed consent
• able and willing to undergo blood sampling for DPYD genotyping, DPD phenotyping and pharmacokinetic analysis

You may not qualify if:

• symptomatic or uncontrolled central nervous system metastases
• patient who cannot submit itself to the formal follow-up for psychological, social, family or geographical reasons
• women who are pregnant or breast-feeding
• women not consenting to use adequate contraceptive precautions during the study
• significant serious pathology or any instable medical condition (cardiac pathology uncontrolled, myocardial infarction within 6 months before enrolment, systemic active uncontrolled infection, cirrhosis (Child-Pugh score C), renal failure (GFR \< 20 ml/min))
• any investigational agent within 4 weeks before enrolment
• cimetidine or sorivudine use (due to drug-drug interactions with 5-fluorouracil and capecitabine)

Sponsors & Collaborators

• Jan Gerard Maring: lead

Study Sites (1)

Isala Hospital Zwolle

Zwolle, 8025 AB, Netherlands

Location

MeSH Terms

Conditions

Gastrointestinal Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PharmD, PhD (Hospital Pharmacist - Clinical Pharmacologist)

Model Details: The study is designed as a single-centre prospective inception cohort study. Study duration per subject will be a maximum 3 months. All gastrointestinal cancer patients scheduled to treatment with fluoropyrimidine based chemotherapy will be asked to participate for the study. All patients will be screened for DPD deficiency by DPYD genotyping. Only 4 most common DPYD variants will be included, including E412E (c.1236G\>A; rs56038477), I560S (\*13; c.1679T\>G; rs55886062), D949V (c.2846A\>T; rs67376798) and IVS14 ds+1G\>A (\*2A; c.1905+1G\>A; rs3918290). Patients will be separated into two groups: DPYD variants and control group.

Study Record Dates

• First Submitted: January 7, 2025
• First Posted: January 17, 2025
• Study Start: February 2, 2020
• Primary Completion: August 22, 2023
• Study Completion: October 31, 2024
• Last Updated: January 17, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)